What are the side effects of zenocutuzumab?

Zenocutuzumab is a bispecific monoclonal antibody that mainly targets HER2 and HER3 >Receptor for the treatment of patients with non-small cell lung cancer (NSCLC) and pancreatic cancer carrying the NRG1 gene fusion. Although it has shown good efficacy in clinical trials, the use of zetolizumab, like other biologics, may be associated with certain side effects. Here's a closer look at its potential side effects.

1. Common side effects

In clinical trials, some common adverse reactions reported by patients taking zetolizumab include:

Gastrointestinal symptoms: such as nausea, vomiting, diarrhea and constipation. These symptoms may be related to the effects of the drug on the gastrointestinal epithelial cells.

Fatigue: Patients may experience fatigue or low energy, which may be related to activation of the immune system or other metabolic changes.

Musculoskeletal pain: includes muscle pain and joint pain, which may be related to immune response or release of inflammatory mediators.

Rash: The skin may develop erythema, itching, or other forms of rash, which may be a sign of an immune response.

2. Serious side effects

Although rare, the use of zetolizumab may cause some serious adverse reactions:

Increased risk of infection: Because zetolizumab may affect immune system function, patients may be more susceptible to infections, such as upper respiratory tract infections or urinary tract infections.

Hypocalcemia: Similar to other treatments targeting HER2, zetolizumab may cause a decrease in serum calcium levels and requires regular monitoring.

Allergic reactions: including anaphylactic shock, angioedema, etc. Although rare, they need to be taken seriously.

Cardiotoxicity: Treatment targetingHER2 may have an impact on cardiac function, such as heart failure, and cardiac function needs to be evaluated regularly.

3. Abnormal laboratory indicators

During the use of zetolizumab, the following laboratory abnormalities may be observed:

Reduced hemoglobin: may lead to anemia symptoms, such as fatigue, dizziness, etc.

Leukopenia: May increase risk of infection, white blood cell count needs to be monitored closely.

Thrombocytopenia: May increase risk of bleeding; platelet levels need to be monitored.

4. Other potential side effects

Although there is currently limited data on the specific side effects of certolizumab, with reference to other similar targeted therapy drugs, such as trastuzumab deruxtecan (Trastuzumab deruxtecan) and certolizumab (Certolizumab), the following side effects may be present:

Interstitial lung disease: manifests as dyspnea, cough, etc., which needs to be identified and treated in time.

Abnormal liver function: It may lead to elevated liver enzymes, and liver function indicators need to be monitored regularly.

5. Notes

Monitoring: During the treatment process, blood routine, liver, kidney and heart functions need to be monitored regularly to detect and deal with potential adverse reactions in a timely manner.

Patient education: Informing patients of possible side effects so that they can identify and report them promptly so that medical staff can take appropriate intervention measures.

Multidisciplinary collaboration: During the treatment process, oncologists should work closely with cardiology, respiratory and other related departments to jointly manage complex situations that may arise.

Zetolizumab, as a new bispecific monoclonal antibody, provides a new treatment option for cancer patients carryingNRG1 gene fusion. However, as with other biologics, their use may be associated with a variety of side effects, including gastrointestinal symptoms, fatigue, and increased risk of infection. During the treatment process, both doctors and patients should pay close attention to these potential adverse reactions and adopt active monitoring and management strategies to ensure the safety and effectiveness of the treatment.

Reference link: https://www.zailaboratory.com